Instrument Inactif

Communiqués Asterias Biotherapeutics Inc OTC Bulletin Board

Actions

US04624N1072

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

08/12/14

ThyssenKrupp : ECHO BONDS : Fitch relève la perspective de ThyssenKrupp à stable

Communiqués

24/01/19	Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
09/11/18	Asterias Biotherapeutics Reports Third Quarter Results	GL
08/11/18	Asterias Biotherapeutics : BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company	BU
08/11/18	Asterias Biotherapeutics : BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update	BU
01/10/18	Asterias Biotherapeutics Announces Facilities and IP License Option Agreements	GL
20/09/18	FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program	GL
04/09/18	Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)	GL
29/08/18	Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference	GL
09/08/18	Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress	GL
31/07/18	Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
26/07/18	Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018	GL
17/07/18	Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
12/07/18	Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke	GL
12/06/18	Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer	GL
05/06/18	Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury	GL
16/05/18	Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress	GL
03/05/18	Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018	GL
02/05/18	Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting	GL
27/04/18	Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference	GL
25/04/18	Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2	GL
15/03/18	Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments	GL
09/03/18	Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018	GL
28/02/18	Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
15/02/18	Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program	GL
04/01/18	Asterias Biotherapeutics Reports Milestone Targets for 2018	GL